Theravance BioPharma
TBPH16.8500.24% ( -0.040 )
Theravance BioPharma (TBPH)
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized...
- Open
- 16.880
- High
- 16.910
- Low
- 16.850
- Prev. Close
- 16.890
- Volume
- 444.15K
- Turnover
- 7.49M
- Avg Price
- 16.874
- Bid/Ask Ratio
- --
- Amplitude
- 0.36%
- 52wk High
- 21.030
- Volume Ratio
- 0.60
- Turnover Ratio
- 1.83%
Theravance BioPharma Analyst Rating
View MoreForecast & Rating
Jul 7, 2026Price forecast
$17.674.85%
Forecast & RatingHold
5analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
News
- StockTitan · Jul 15 at 09:00 PM
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 | ZYME Stock News
- prnewswire · Jul 9 at 01:45 PM
14:43 ET$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBPH, IRDM, LCII, and PATK
- Market Beat · Jul 9 at 05:29 AM
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Hold" by Analysts
- Tip Ranks · Jul 8 at 09:02 PM
Major Theravance Biopharma Investor Makes Notable Stock Move
- PUBT · Jul 8 at 03:14 PM
Theravance Biopharma 10% owner Eli Samaha disposes of USD 119,359 in common shares
- PUBT · Jul 1 at 06:34 PM
Theravance Biopharma 10% owner Eli Samaha sells 336,697 common shares worth $5.78 million
